Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Hepatocellular × lanreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 11 Carcinoid Tumor 5 Acromegaly 3 Serotonin Syndrome 2 Pituitary Neoplasms 2 Gastro-enteropancreatic neuroendocrine tumor 2 Prostatic Neoplasms 1 Pheochromocytoma 1 Peritoneal Neoplasms 1 Paraganglioma 1 Pancreatic Neoplasms 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Neoplasms 1 Neoplasm Metastasis 1 Intestinal Obstruction 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gigantism 1 Gastrointestinal Neoplasms 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Carcinoid Heart Disease 1 Adenoma, Islet Cell 1

Interventions

Sorafenib 181 lenvatinib 109 Bevacizumab 96 Nivolumab 68 pembrolizumab 58 atezolizumab 57 Radiosurgery 54 durvalumab 53 Oxaliplatin 49 Fluorouracil 45 sintilimab 41 Doxorubicin 40 apatinib 38 tislelizumab 34 Leucovorin 33 camrelizumab 32 tremelimumab 31 Radiotherapy 29 Radiofrequency Ablation 28 Magnetic Resonance Spectroscopy 25 Capecitabine 25 Folfox protocol 24 Cyclophosphamide 24 Cisplatin 23 Ipilimumab 22 Hepatectomy 22 cabozantinib 21 Gemcitabine 20 regorafenib 19 Ethiodized Oil 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00495846 2009-08-17

SS-HCC

Federico II University

Phase 2/3 Completed

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡